Tag Archives: Wegovy

Novo ObesityWeek 2026 Presentations; MiniMed Fit FDA Clearance; Corxel Ph2 Oral GLP-1RA Results

Three cardiometabolic-related news items have been observed: Novo presented additional Ph3 results of cagrisema at ObesityWeek 2026 (view press release); MiniMed received FDA clearance for MiniMed Fit (view press release); and Corxel shared full Ph2 data of its oral GLP-1RA for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Arrowhead Q3 ’26 Earnings; Lilly Breaks Ground on US Manufacturing Facility; Tandem Mobi Tubeless FDA Clearance; November CHMP Highlights; AbbVie Skyrizi + Amylin Combo PsO Study; Vivani Topline Ph1 Sema Implant Data

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Lilly, Tandem Diabetes Care, EMA, AbbVie, and Vivani Medical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

FDA Cuts CNPV Program; Blackstone Funds Pfizer’s Obesity Efforts; Berobenatide SUI Study; Orforglipron Approved in China; Zealand and Altimmune Q3 ’26 Earnings; Novo Zenagamtide AMBITION Studies; Novo Partners with DJ Khaled

A series of cardiometabolic-related news items has been observed from FDA, Pfizer, Lilly, Zealand Pharma, Altimmune, and Novo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Raises FY 2026 Guidance as Wegovy Pill Revives Investor Sentiment; Q3 ’26 Earnings

Novo hosted its Q3 ’26 earnings call and provided updates across its diabetes and obesity businesses (press release; slides). Following the call, Novo’s stock is up +7% after raising its FY 2026 adjusted sales guidance to +2% to +6% (from a prior range of 0% to +6%), reflecting an improved outlook across both business segments. Additionally, Wegovy pill delivered a strong quarter with sales of ~$831M exceeding consensus expectations, further contributing to a recovery in investor sentiment. Separately, Novo announced that CFO Karsten Munk Knudsen will step down at the end of 2026 and be succeeded by Luigi La Corte, who currently serves as CFO of Galderma (view LinkedIn post). Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Key Press Releases (September 29)

On the second day of EASD 2026, seven key news items were observed from Novo/Hengrui, Lilly, Caspian Therapeutics, Merck/Cyprumed GmbH, and Oura. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Preview: Where FENIX will be paying attention and why

With EASD 2026 approaching (September 28-October 2; Milan, Italy), FENIX has compiled a short list of key sessions and presentations that warrant close attention. While EASD brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately have an outsized impact on the field for years to come.

This content is for Read Less members only.
Already a member? Log in here

Onswik FDA Approval; Lilly Medicare GLP-1 Bridge Program Market Share; BI + WHO Global Metabolic Health Collaboration; Roche + Atavistik Partner for Allosteric Drug Discovery; Aqua Medical T2DM Endoscopic Procedure; Biolinq Shine OTC FDA Clearance; Rezera RESOLVE-1 AHA Presentation

A series of cardiometabolic-related news items has been observed from Lilly, BI/WHO, Roche/Atavistik Bio, Aqua Medical, Biolinq, and Rezera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Positive Pants Part 2: Novo 2026 Capital Markets Day Highlights and Analysis

Part 2 of FENIX’s 2026 Novo CMD coverage recaps commentary on US commercial operations, global manufacturing & supply, and international operations. Each of these three components is viewed as integral to Novo’s future success while it attempts to maintain (and grow) its place in the CVRM market ahead of the onslaught of obesity competitors looking to eat its lunch.

This content is for Read Less members only.
Already a member? Log in here

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here